Compare PMAX & DCOY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMAX | DCOY |
|---|---|---|
| Founded | 2019 | N/A |
| Country | Hong Kong | United States |
| Employees | 53 | 11 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7M | 4.2M |
| IPO Year | N/A | N/A |
| Metric | PMAX | DCOY |
|---|---|---|
| Price | $2.00 | $5.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 213.6K | 14.0K |
| Earning Date | 05-12-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.53 |
| 52 Week High | $5.20 | $9.57 |
| Indicator | PMAX | DCOY |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 50.85 |
| Support Level | $1.70 | $4.98 |
| Resistance Level | $2.87 | $6.47 |
| Average True Range (ATR) | 0.30 | 0.97 |
| MACD | -0.06 | -0.15 |
| Stochastic Oscillator | 28.18 | 30.82 |
Powell Max Ltd operates as a financial communications platform supporting listed companies and IPO applicants throughout the capital markets lifecycle. Substantially all of the company's revenue is generated from Hong Kong. The group focused on supporting the disclosure, reporting, and transaction needs of corporate clients and their advisors. Its mission is to combine industry knowledge, execution capabilities, and a commitment to service to deliver accurate, timely, and reliable solutions for customers.
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.